Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease

被引:56
作者
Sigvant, Birgitta [1 ,5 ]
Wiberg-Hedman, Katarina [2 ]
Bergqvist, David [3 ]
Rolandsson, Olov [4 ]
Wahlberg, Eric [5 ]
机构
[1] Cent Hosp Karlstad, Dept Surg, Stockholm, Sweden
[2] Cent Hosp Karlstad, Dept Med Epidemiol & Stat, Stockholm, Sweden
[3] Univ Uppsala Hosp, Dept Surg, Stockholm, Sweden
[4] Umea Univ, Dept Publ Hlth & Clin Med, Stockholm, Sweden
[5] Karolinska Univ Hosp & Inst, Dept Vasc Surg, Stockholm, Sweden
来源
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION | 2009年 / 16卷 / 01期
关键词
ankle-brachial index; peripheral arterial disease; primary drug prevention; risk factors; sex differences; ANKLE-BRACHIAL INDEX; INTERMITTENT CLAUDICATION; PHYSICAL-ACTIVITY; LIMB ISCHEMIA; PREVALENCE; SMOKING; ASSOCIATION; POPULATION; MORTALITY; RAMIPRIL;
D O I
10.1097/HJR.0b013e32831c1383
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine cardiovascular comorbidities and use of cardiovascular disease preventive drugs in patients with peripheral arterial disease (PAD), with special attention to sex differences. Design A cross-sectional point-prevalence study. Patients A population sample of patients that are 60-90 years old. Setting Primary care areas in four Swedish regions. Main outcome measures Prevalence of PAD stages, comorbidities and medication use. Results The prevalence of any type of PAD was 18.0% (range 16-20), of asymptomatic peripheral arterial disease (APAD) was 11.1 % (range 9-13), intermittent claudication was 6.8% (range 6.5-71), and of critical limb ischemia (CLI) was 1.2% (range 1.0-1.5). APAD and CLI were more common in women. Statins were used by 175% (range 16.9-18.2), 29.4% (range 29.0-30.1), and 30.3% (range 29.9-30.8) of the patients with APAD, intermittent claudication, and CLI, respectively, and antiplatelet therapy was reported by 34.1% (range 33.7-34-3), 47.6% (range 47.3-47.9), and 60.2% (range 59.1-60.7). The odds ratio for having APAD was 1.7 (range 1.2-2.4) for women with a smoking history of 10 years in relation to nonsmokers. This association was observed only in men who had smoked for at least 30 years or more. Preventive drug use was more common in men with PAD. Compared with women they had an odds ratio of 1.3 (range 1.1-1.5) for lipid-lowering therapy, 1.3 (range 1.0-1.7) for beta-blockers or angiotensin-converting enzyme inhibitors, and 1.5 (range 1.2-1.9) for antiplatelet therapy. Conclusion The patients' risk factor profiles differed among the PAD stages. Smoking duration already seemed to be a risk factor for women with PAD after 10 years of smoking, as compared with 30 years for men, and fewer women reported use of preventive medication. These observations may partly explain the sex differences in prevalence that were observed. Eur J Cardiovasc Prev Rehabil 16:39-46 (C) 2009 The European Society of Cardiology
引用
收藏
页码:39 / 46
页数:8
相关论文
共 36 条
  • [1] Smoking and gender
    Bolego, C
    Poli, A
    Paoletti, R
    [J]. CARDIOVASCULAR RESEARCH, 2002, 53 (03) : 568 - 576
  • [2] Patterns and correlates of physical activity among US women 40 years and older
    Brownson, RC
    Eyler, AA
    King, AC
    Brown, DR
    Shyu, YL
    Sallis, JF
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (02) : 264 - 270
  • [3] MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE
    CRIQUI, MH
    LANGER, RD
    FRONEK, A
    FEIGELSON, HS
    KLAUBER, MR
    MCCANN, TJ
    BROWNER, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (06) : 381 - 386
  • [4] High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study
    Diehm, C
    Schuster, A
    Allenberg, JR
    Darius, H
    Haberl, R
    Lange, S
    Pittrow, D
    von Stritzky, B
    Tepohl, G
    Trampisch, HJ
    [J]. ATHEROSCLEROSIS, 2004, 172 (01) : 95 - 105
  • [5] Egan Brent M, 2005, J Clin Hypertens (Greenwich), V7, P409, DOI 10.1111/j.1524-6175.2005.04486.x
  • [6] FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
  • [7] European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
    Graham, Ian
    Atar, Dan
    Borch-Johnsen, Knut
    Boysen, Gudrun
    Burell, Gunilla
    Cifkova, Renata
    Dallongeville, Jean
    De Backer, Guy
    Ebrahim, Shah
    Gjelsvik, Bjorn
    Herrman-Lingen, Christoph
    Hoes, Arno
    Humphries, Steve
    Knapton, Mike
    Perk, Joep
    Priori, Silvia G.
    Pyorala, Kalevi
    Reiner, Zeljko
    Ruilope, Luis
    Sans-Menendez, Susana
    Reimer, Wilma Scholte Op
    Weissberg, Peter
    Wood, David
    Yarnell, John
    Zamorano, Jose Luis
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2007, 14 : E1 - E40
  • [8] PAD awareness, risk, and treatment: new resources for survival - the USA PARTNERS program
    Hirsch, AT
    Hiatt, WR
    [J]. VASCULAR MEDICINE, 2001, 6 (03) : 9 - 12
  • [9] Hooi JD, 1998, SCAND J PRIM HEALTH, V16, P177
  • [10] CORONARY-ARTERY DISEASE AND WOMEN
    JACKSON, G
    [J]. BRITISH MEDICAL JOURNAL, 1994, 309 (6954) : 555 - 557